MyKybella

DOWNLOAD YOUR
GUIDE HERE

VIEW AND
DOWNLOAD
Kybella conversation

A.C.T. NOW

With KYBELLA®, we use the acronym A.C.T. (Assess. Consult. Treat.) to summarize the key phases of the patient journey. It’s an easy way to introduce KYBELLA® to your patients.

Kybella conversation

ASSESS

Explore who is right for KYBELLA® using a simple series of assessments to determine candidacy

Kybella conversation

CONSULT

Open conversations about KYBELLA® and your patients’ desired aesthetic goals using robust consultation tips

Kybella conversation

TREAT

Strengthen your treatment planning and injection technique using this step-by-step guide

HELPFUL WEBSITES

PLEASE CONTACT YOUR ALLERGAN AESTHETICS REPRESENTATIVE
IF YOU WOULD LIKE PRINTED TOOLS FOR YOUR PRACTICE!

Indication

KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

Important safety information Contraindications

KYBELLA® is contraindicated in the presence of infection at the injection sites.

Warnings and Precautions Marginal Mandibular Nerve Injury

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia

Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising

In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures

To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury.

Injection Site Alopecia

Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis

Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

Adverse Reactions

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

Reference: 1. KYBELLA® Prescribing Information, May 2020.